Information Provided By:
Fly News Breaks for February 15, 2018
Feb 15, 2018 | 05:18 EDT
Citi analyst Yigal Nochomovitz added Puma Biotechnology to his firm's U.S. Focus List citing "high conviction" on the name and the Nerlynx launch in breast cancer. Even with yesterday's 11% rally, the stock is trading at roughly 10 times the 2018 consensus Nerlynx revenue estimate of $220M and two times a peak U.S. sales estimate of $1.1B, Nochomovitz tells investors in a research note . He believes Puma's U.S. opportunity alone is worth $90 per share. The analyst keeps a Buy rating on the shares with a $146 price target.
News For PBYI From the Last 2 Days
There are no results for your query PBYI
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.